Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antiemetics Drugs Market

Antiemetics Drugs Market Share

Report ID: GMI10262
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Antiemetics Drugs Market Share

The antiemetics drugs industry is characterized by intense competition, involving both major global companies and smaller to medium-sized companies vying for market dominance. Key to market strategy is the consistent launch of innovative products utilizing various technologies. Major industry leaders play a significant role in driving innovation by making substantial investments in research and development. Moreover, strategic partnerships, acquisitions, and mergers play crucial roles in strengthening market positions and enhancing international presence.

Antiemetics Drugs Market Companies

Some of the eminent market participants operating in the antiemetics drugs industry include:

Astellas Pharma Inc.
Baxter International Inc.
Cipla Limited
Eagle Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Limited
GSK plc
Hikma Pharmaceuticals PLC
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Torrent Pharmaceuticals Limited
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global antiemetics drugs industry was valued at USD 6.7 billion in 2023 and is anticipated to register 5.6% CAGR between 2024 and 2032, driven by growing availability of reimbursement and coverage for antiemetic drugs.

The chemotherapy induced nausea and vomiting (CINV) segment in the market accounted for USD 3.1 billion in 2023 primarily due to the high incidence of cancer and the critical need for effective management.

U.S. antiemetics drugs market is projected to reach USD 4.2 billion by 2032, driven by innovations in drug formulations and delivery systems.

Astellas Pharma Inc., Baxter International Inc., Cipla Limited, Eagle Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, GSK plc, Hikma Pharmaceuticals PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG, among others.